Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1985 1
1988 1
1990 1
1993 5
1994 5
1995 3
1996 1
1997 3
1998 3
1999 6
2000 10
2001 7
2002 9
2003 12
2004 10
2005 18
2006 16
2007 14
2008 18
2009 18
2010 16
2011 22
2012 23
2013 24
2014 24
2015 21
2016 23
2017 20
2018 14
2019 16
2020 24
2021 25
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

376 results
Results by year
Filters applied: . Clear all
Page 1
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Magiorakos AP, et al. Among authors: carmeli y. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. Clin Microbiol Infect. 2012. PMID: 21793988 Free article.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Among authors: carmeli y. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051
The negative impact of antibiotic resistance.
Friedman ND, Temkin E, Carmeli Y. Friedman ND, et al. Among authors: carmeli y. Clin Microbiol Infect. 2016 May;22(5):416-22. doi: 10.1016/j.cmi.2015.12.002. Epub 2015 Dec 17. Clin Microbiol Infect. 2016. PMID: 26706614 Free article. Review.
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Paul M, et al. Among authors: carmeli y. Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16. Lancet Infect Dis. 2018. PMID: 29456043 Clinical Trial.
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Carmeli Y, et al. Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20. Lancet Infect Dis. 2016. PMID: 27107460 Free article. Clinical Trial.
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Grundmann H, et al. Among authors: carmeli y. Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18. Lancet Infect Dis. 2017. PMID: 27866944 Free article.
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators. Gutiérrez-Gutiérrez B, et al. Among authors: carmeli y. Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22. Lancet Infect Dis. 2017. PMID: 28442293
Reply to Apisarnthanarak and Apisarnthanarak.
Nutman A, Carmeli Y. Nutman A, et al. Among authors: carmeli y. Clin Infect Dis. 2020 Nov 5;71(8):2025. doi: 10.1093/cid/ciaa047. Clin Infect Dis. 2020. PMID: 32297924 No abstract available.
Reply to Wilson et al.
Dickstein Y, Leibovici L, Carmeli Y, Daikos G, Durante-Mangoni E, Friberg LE, Paul M. Dickstein Y, et al. Among authors: carmeli y. Clin Infect Dis. 2020 Aug 22;71(5):1358-1359. doi: 10.1093/cid/ciz1100. Clin Infect Dis. 2020. PMID: 31734694 No abstract available.
376 results